AdvanTIG-202: Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Previously Treated Recurrent or Metastatic Cervical Cancer
BeiGene
BeiGene
SOLTI Breast Cancer Research Group
First Affiliated Hospital of Guangxi Medical University
Peking Union Medical College Hospital
First Affiliated Hospital of Guangxi Medical University
Australia New Zealand Gynaecological Oncology Group
Zhejiang Cancer Hospital
Peking Union Medical College Hospital